Certain immunophenotypic markers may identify a patient with acute promyelocytic leukemia who may have a worse prognosis. A patient at increased risk for a poor prognosis may benefit from a more aggressive or experimental therapy.


Patient selection: acute promyelocytic anemia (APML)


Immunophenotypes associated with a worse prognosis:

(1) CD56

(2) CD34

(3) CD2

(4) CD15 (may be associated with bcr1 expression)


These combined with a high white blood cell count prior to therapy (> 10,000 per µL) can help to identify a patient who may have a poor prognosis.


To read more or access our algorithms and calculators, please log in or register.